---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071370"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:14:36.122568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4

## Summary
- Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.
- Cash, equivalents and short-term investments $124.9M as of March 31, 2025; funds operations to end of 2026.
- R&D expenses $13.5M (incl. $1.0M SBC) vs $7.4M prior year; G&A $4.4M vs $3.5M.
- Tegoprubart used in second genetically modified pig kidney transplant at Mass General; patient discharged without dialysis.
- Topline Phase 2 BESTOW results on track for Q4 2025; interim Phase 1b data expected August 2025.

## SEC filing metadata
- accession: 0000950170-25-071370
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/0000950170-25-071370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071370
- JSON: https://secwatch.observer/filing/0000950170-25-071370.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.